Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta-Cell Function and Prevented a Conversion Rate to MTG and DM2 in Metformin Intolerant PCOS with High Metabolic Risk

被引：0
|
作者：
Ferjan, Simona
Jensterle, Mojca
Janez, Andrej
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2145-P
引用
收藏
页码：A563 / A563
页数：1
相关论文
共 27 条
  • [1] The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates retinal endothelial cell dysfunction triggered by inflammation
    Goncalves, Andreia
    Almeida, Luisa
    Silva, Ana Paula
    Fontes-Ribeiro, Carlos
    Ambrosio, Antonio F.
    Cristovao, Armando
    Fernandes, Rosa
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 102 : 833 - 838
  • [2] Serum Level of Soluble CD26/DPP-4 Predicts the Response to Sitagliptin, a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, in Patients With Type 2 Diabetes Inadequately Controlled by Metformin and/or Sulfonylurea
    Aso, Yoshimasa
    Inukai, Toshihiko
    Kasai, Kikuo
    DIABETES, 2012, 61 : A240 - A240
  • [3] Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea
    Aso, Yoshimasa
    Ozeki, Noriyuki
    Terasawa, Tomoko
    Naruse, Rika
    Hara, Kenji
    Suetsugu, Mariko
    Takebayashi, Kohzo
    Shibazaki, Mitsuei
    Haruki, Kohsuke
    Morita, Kimio
    Inukai, Toshihiko
    TRANSLATIONAL RESEARCH, 2012, 159 (01) : 25 - 31
  • [4] Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach
    Xu, L.
    Man, C. Dalla
    Charbonnel, B.
    Meninger, G.
    Davies, M. J.
    Williams-Herman, D.
    Cobelli, C.
    Stein, P. P.
    DIABETES OBESITY & METABOLISM, 2008, 10 (12): : 1212 - 1220
  • [5] Twelve-week efficacy and tolerability of sitagliptin, a Dipeptidyl Peptidase-4 (DPP-4) inhibitor, in Japanese patients with type 2 diabetes
    Nonaka, K.
    Kakikawa, T.
    Sato, A.
    Okuyama, K.
    Fujimoto, G.
    Hayashi, N.
    Suzuki, H.
    Hirayama, Y.
    Stein, P. P.
    DIABETOLOGIA, 2006, 49 : 25 - 26
  • [6] The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves insulin sensitivity and β-cell function in subjects with impaired fasting glucose
    Jacobsen, Lisbeth V.
    Hindsberger, Charlotte
    Robson, Richard
    Zdravkovic, Milan
    DIABETES, 2007, 56 : A137 - A137
  • [7] Dipeptidyl Peptidase-4 (Dpp-4) Inhibitor (Sitagliptin) as a Novel Treatment Agent for Nonalcoholic Fatty Liver Disease Patients With Type 2 Diabetes Mellitus
    Tomeno, Wataru
    Yoneda, Masato
    Imajo, Kento
    Mawatari, Hironori
    Kirikoshi, Hiroyuki
    Saito, Satoru
    Shibata, Wataru
    Yoneda, Kyoko
    Endo, Hiroki
    Kubota, Kensuke
    Nakajima, Atsushi
    GASTROENTEROLOGY, 2012, 142 (05) : S1017 - S1017
  • [8] Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improved β cell function in patients with type 2 diabetes:: a model-based analysis
    Xu, L.
    Dalla Man, C.
    Cobelli, C.
    Williams-Herman, D.
    Meininger, G.
    Khatami, H.
    Stein, P.
    DIABETOLOGIA, 2006, 49 : 396 - 397
  • [9] Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
    Goldenberg, Ronald
    Gantz, Ira
    Andryuk, Paula J.
    O'Neill, Edward A.
    Kaufman, Keith D.
    Lai, Eseng
    Wang, Yin Na
    Suryawanshi, Shailaja
    Engel, Samuel S.
    DIABETES OBESITY & METABOLISM, 2017, 19 (03): : 394 - 400
  • [10] Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes
    Brazg, R.
    Xu, L.
    Dalla Man, C.
    Cobelli, C.
    Thomas, K.
    Stein, P. P.
    DIABETES OBESITY & METABOLISM, 2007, 9 (02): : 186 - 193
123